B
FOMX

Baird’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Baird’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$139K Buy
+15,000
New +$134K ﹤0.01% 1259

Other funds holding FOMX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Baird's FOMX Position: Q1 2015 in Review

Baird opened a new position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2015: 15,000 shares worth $139K. The stake represents ﹤0.01% of the portfolio and ranks #1259 among its holdings.

31 funds tracked by Wall St. Rank hold FOMX as of Q1 2015.

  • Baird held 15,000 shares of Foamix Pharmaceuticals Ltd. Ordinary Shares worth $139K as of Q1 2015.
  • Foamix Pharmaceuticals Ltd. Ordinary Shares was a new Baird position in Q1 2015.
  • Foamix Pharmaceuticals Ltd. Ordinary Shares made up ﹤0.01% of Baird's portfolio in Q1 2015, its #1259 holding.
  • 31 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.